Corbus CFO sells 12,000 shares under 10b5-1 plan

Corbus Pharmaceuticals Holdings, Inc. Chief Financial Officer Sean F. Moran reported a sale of 12,000 shares of common stock on August 7, 2026.

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. Chief Financial Officer Sean F. Moran reported a sale of 12,000 shares of common stock on August 7, 2026. The shares were sold at a weighted average price of $10.0809 per share under a Rule 10b5-1 trading plan adopted on March 11, 2026. Following this transaction, Moran holds 84,694 shares directly, including 68,795 unvested RSUs that remain subject to their vesting schedules.

Insider Trade Summary 10b5-1

Net Seller: 12,000 shares

Net Sell 1 txn

Insider Moran Sean F.

Role Chief Financial Officer

Sold 12,000 shs ($121K)

Type	Security	Shares	Price	Value
Sale	Common Stock, par value $0.0001 per share F1, F2, F3	12,000	$10.0809	$121K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 84,694 shares (Direct)

Footnotes (3)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. This amount includes 68,795 unvested RSUs subject to each grant's vesting schedule as previously reported.

Key Figures

Shares sold: 12,000 shares Weighted average sale price: $10.0809 per share Shares held after transaction: 84,694 shares +1 more

4 metrics

Shares sold 12,000 shares Common stock sold on August 7, 2026 by CFO Sean F. Moran

Weighted average sale price $10.0809 per share Price for 12,000 shares sold in multiple transactions, range $10.00–$10.25

Shares held after transaction 84,694 shares Direct common stock holdings of Sean F. Moran following the sale

Unvested RSUs included in holdings 68,795 RSUs Unvested RSUs included within post-transaction total shares, subject to vesting

Key Terms

Rule 10b5-1 trading plan, restricted stock units, weighted average price

3 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"This amount includes 68,795 unvested RSUs subject to each grant's vesting"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Corbus Pharmaceuticals (CRBP) report for Sean F. Moran?

Corbus Pharmaceuticals reported that CFO Sean F. Moran sold 12,000 shares of common stock on August 7, 2026 at a weighted average price of $10.0809 per share in an open market or private transaction.

Was the CRBP CFO’s August 7, 2026 share sale under a 10b5-1 plan?

Yes. The sale by CRBP CFO Sean F. Moran on August 7, 2026 was effected pursuant to a Rule 10b5-1 trading plan that he adopted on March 11, 2026.

How many CRBP shares did the CFO retain after the reported sale?

After selling 12,000 shares, CRBP CFO Sean F. Moran directly holds 84,694 shares of common stock. This total includes 68,795 unvested RSUs that remain subject to each grant’s vesting schedule.

What price range were CRBP shares sold at in the CFO’s August 2026 transaction?

The reported price is a weighted average of $10.0809 per share. The 12,000 CRBP shares were sold in multiple transactions at prices ranging from $10.00 to $10.25 per share.

What type of security did CRBP’s CFO sell in the Form 4 transaction?

CRBP’s CFO, Sean F. Moran, sold common stock with a par value of $0.0001 per share. The reported transaction involved 12,000 shares classified as a non-derivative security.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/10/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moran Sean F.

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MASSACHUSETTS 02062

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	08/07/2026		S(1)		12,000	D	$10.0809(2)	84,694(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This amount includes 68,795 unvested RSUs subject to each grant's vesting schedule as previously reported.

	/s/Sean Moran	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)